Drug Information

Drug General Information
Drug ID
D0X7KB
Former ID
DAP000255
Drug Name
Lisuride
Synonyms
Lisurida; Lisuridum; Lysurid; Lysuride; Lisuride [INN]; Lysuride Hydrogen Maleate; Methylergol Carbamide; Arolac (TN); Cuvalit (TN); Dipergon (TN); Dopergin (TN); Dopergine (TN); Lisurida [INN-Spanish]; Lisuride (INN); Lisuridum [INN-Latin]; Lysenyl Forte (TN); Prolacam (TN); Revanil (TN); Lisuride Maleate (1:1); N'-((8alpha)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylurea; 1,1-diethyl-3-[(8alpha)-6-methyl-9,10-didehydroergolin-8-yl]urea; 3-(9,10-Didehydro-6-methylergolin-8alpha-yl)-1,1-diethylurea
Drug Type
Small molecular drug
Indication Parkinson's disease [ICD9: 332; ICD10:G20] Approved [467639], [536217]
Fibrosis [ICD9: 709.2; ICD10:L90.5] Phase 3 [521931]
Therapeutic Class
Antiparkinson Agents
Company
IVAX Pharmaceuticals
Structure
Download
2D MOL

3D MOL
Formula
C20H26N4O
InChI
InChI=1S/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)/t14-,18+/m0/s1
InChIKey
BKRGVLQUQGGVSM-KBXCAEBGSA-N
CAS Number
CAS 18016-80-3
PubChem Compound ID
28864
PubChem Substance ID
7979782, 8170644, 10321508, 11466134, 11467254, 11485767, 14827074, 16304643, 34671274, 46505557, 47216935, 47440423, 47515485, 47810926, 47885573, 48416176, 49698348, 50060231, 56464344, 57309764, 57310710, 76836308, 92125058, 96024822, 103408740, 103914001, 103952701, 104303892, 124749968, 124893624, 127339697, 127339698, 127339699, 127339700, 127339701, 127529620, 134337569, 134340181, 134340461, 135269077, 135650525, 137001465, 137225007, 142950042, 160963934, 163304387, 164761611, 179150133, 224890570, 226428258
ChEBI ID
ChEBI:51164
SuperDrug ATC ID
G02CB02; N02CA07
SuperDrug CAS ID
cas=018016803
Target and Pathway
Target(s) D(2) dopamine receptor Target Info Agonist [536452], [536478], [537763]
KEGG Pathway Rap1 signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholism
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathway
Reactome Dopamine receptors
G alpha (i) signalling events
WikiPathways Hypothetical Network for Drug Addiction
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Genes and (Common) Pathways Underlying Drug Addiction
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic Neurons
References
Ref 467639(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 43).
Ref 521931ClinicalTrials.gov (NCT00408915) Continuous Application of Lisuride in Parkinson's Disease by Subcutaneous Infusion. U.S. National Institutes of Health.
Ref 536217Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol. 2006 Mar-Apr;29(2):80-6.
Ref 536452Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs. 2007;21(8):677-92.
Ref 536478Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 2007 Sep;6(9):826-9.
Ref 537763Tolerance to some behavioural effects of lisuride, a dopamine receptor agonist, and reverse tolerance to others, after repeated administration. Neuropharmacology. 1985 Mar;24(3):199-206.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.